Chuikyo Talks Over Sales Criteria to Trigger Possible Xocova Re-Pricing; Is 3-Month-Based Estimate an Overestimate?

A key Japanese reimbursement policy panel on February 8 discussed the possible post-listing re-pricing of Shionogi’s COVID-19 pill Xocova (ensitrelvir) to brace for the scenario of its rapid market expansion. The focus was on the threshold and how to estimate...read more